Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 7/20 | 0.74 |
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 5/20 | 0.74 |
| ▸ | RAB9A | P51151 | 4/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.72 |
| ▸ | TP53 | P04637 | 1/20 | 0.72 |
| ▸ | PKM | P14618 | 1/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.68 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.66 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4254145 | 0.88 | MEN1 (0.80) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL4248472 | 0.88 | KMT2A (0.70) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL10055020 | 0.87 | NPC1 (0.94) | KMT2ANPC1RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL1337652 | 0.87 | MAPT (0.77) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL1984342 | 0.86 | KMT2A (0.69) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL13391762 | 0.86 | KMT2A (0.69) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL1337428 | 0.86 | MEN1 (0.76) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL4118579 | 0.85 | KMT2A (0.72) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL4256368 | 0.84 | NPC1 (1.00) | KMT2ANPC1MEN1RAB9AALDH1A1 | |
| SCHEMBL16494872 | 0.84 | MEN1 (0.81) | KMT2ANPC1MEN1RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108084096-A | 2- phenyl pyrimidine classes compound, preparation method and medical usage | 中国药科大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | NOVOGEN LIMITED (AU) | 2017-06-15 | — | — | US | disclosed |
| EP-3074378-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen Ltd. (AU) | 2016-10-05 | — | — | EP | disclosed |
| CN-105916841-A | Functionalised and substituted indoles as anti-cancer agents | 诺沃根公司 | 2016-08-31 | — | — | CN | disclosed |
| WO-2015074123-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2015-05-28 | — | — | WO | disclosed |
| EP-2338059-B1 | Ligands for aggregated tau molecules | WISTA LAB LTD (SG) | 2015-04-08 | — | — | EP | disclosed |
| US-8927584-B2 | Synthesis of 2-(4-aminophenyl)benzothiazole derivatives and use thereof | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2015-01-06 | — | — | US | disclosed |
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-8895313-B2 | Ligands for aggregated tau molecules | WISTA LABORATORIES LTD. (SG) | 2014-11-25 | — | — | US | disclosed |
| US-20140046290-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | KAOHSIUNG MEDICAL UNIVERSITY (TW) | 2014-02-13 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. | 2011-07-14 | — | — | US | disclosed |
| EP-2338059-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | Wista Laboratories Ltd. (SG) | 2011-06-29 | — | — | EP | disclosed |
| WO-2010034982-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | WISTA LABORATORIES LTD. (SG) | 2010-04-01 | — | — | WO | disclosed |
| US-6211242-B1 | CARDIOVASCULAR DISORDERS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-03 | — | — | US | disclosed |
| EP-0757670-B1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO (JP) | 1999-01-13 | — | — | EP | disclosed |
| US-5728835-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | TOA EIYO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0757670-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-02-12 | — | — | EP | disclosed |
| WO-1995029152-A1 | BENZAMIDE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-11-02 | — | — | WO | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171739-A1 | LIGANDS FOR AGGREGATED TAU MOLECULES | MAPT, PRNP, MAP4 | KMT2A 3452/4885NPC1 1265/4885MEN1 3205/4885 |
| US-20170166555-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | TPM3, TPM4, TNNI3 | KMT2A 2215/4885NPC1 4458/4885MEN1 3325/4885 |
| US-20140046290-A1 | SYNTHESIS OF 2-(4-AMINOPHENYL)BENZOTHIAZOLE DERIVATIVES AND USE THEREOF | CCNT1, PPOX, TPT1 | KMT2A 2192/4885NPC1 1573/4885MEN1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.